Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) Equity Average (2016 - 2025)

Neuroone Medical Technologies' Equity Average history spans 12 years, with the latest figure at $6.7 million for Q4 2025.

  • For Q4 2025, Equity Average rose 258.62% year-over-year to $6.7 million; the TTM value through Dec 2025 reached $6.7 million, up 258.62%, while the annual FY2025 figure was $3.9 million, 11.64% up from the prior year.
  • Equity Average reached $6.7 million in Q4 2025 per NMTC's latest filing, down from $7.6 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $14.5 million in Q1 2022 to a low of $1.9 million in Q4 2024.
  • Average Equity Average over 5 years is $6.7 million, with a median of $6.4 million recorded in 2021.
  • Peak YoY movement for Equity Average: surged 1161.06% in 2021, then crashed 64.78% in 2024.
  • A 5-year view of Equity Average shows it stood at $11.3 million in 2021, then fell by 21.0% to $8.9 million in 2022, then crashed by 39.99% to $5.3 million in 2023, then tumbled by 64.78% to $1.9 million in 2024, then skyrocketed by 258.62% to $6.7 million in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Equity Average are $6.7 million (Q4 2025), $7.6 million (Q3 2025), and $4.7 million (Q2 2025).